[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Corbus Pharmaceuticals Hldgs Inc (CRBP)

Corbus Pharmaceuticals Hldgs Inc (CRBP)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 188,204
  • Shares Outstanding, K 18,671
  • Annual Sales, $ 0 K
  • Annual Income, $ -78,540 K
  • EBIT $ -107 M
  • EBITDA $ -108 M
  • 60-Month Beta 2.59
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 1.92

Options Overview Details

View History
  • Implied Volatility 114.29% (+1.23%)
  • Historical Volatility 46.38%
  • IV Percentile 19%
  • IV Rank 8.51%
  • IV High 489.47% on 02/20/26
  • IV Low 79.39% on 04/09/26
  • Expected Move (DTE 2) 0.47 (4.68%)
  • Put/Call Vol Ratio 0.24
  • Today's Volume 222
  • Volume Avg (30-Day) 436
  • Put/Call OI Ratio 0.05
  • Today's Open Interest 34,440
  • Open Int (30-Day) 29,855
  • Expected Range 9.52 to 10.46

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 11 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/26
See More
  • Average Estimate $-1.40
  • Number of Estimates 6
  • High Estimate $-0.95
  • Low Estimate $-1.91
  • Prior Year $-1.90
  • Growth Rate Est. (year over year) +26.32%

Price Performance

See More
Period Period Low Period High Performance
1-Month
8.61 +15.96%
on 07/31/26
10.75 -7.07%
on 08/18/26
+0.98 (+10.88%)
since 07/17/26
3-Month
7.12 +40.31%
on 06/02/26
12.88 -22.44%
on 05/22/26
+0.84 (+9.18%)
since 05/19/26
52-Week
7.12 +40.31%
on 06/02/26
20.56 -51.41%
on 10/20/25
+0.86 (+9.42%)
since 08/19/25

Most Recent Stories

More News
Corbus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

NORWOOD, Mass., Aug. 17, 2026 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP), a clinical-stage company focused on new therapies in oncology and obesity, today announced the...

CRBP : 9.99 (-0.89%)
Corbus Pharmaceuticals: Q2 Earnings Snapshot

Corbus Pharmaceuticals: Q2 Earnings Snapshot

CRBP : 9.99 (-0.89%)
Corbus Pharmaceuticals Reports Q2 2026 Financial Results and Provides a Corporate Update

Obtained FDA clearance to proceed with registrational study (TEMPO-1) of CRB-701 in 2L oropharyngeal cancer and expect to initiate enrollment in September 2026 Concluded last patient last visit in CANYON-1...

CRBP : 9.99 (-0.89%)
Corbus Pharmaceuticals Announces Last Patient Last Visit in CANYON-1 Study of CRB-913 for the Treatment of Obesity

Dose-finding Phase 1b study (n=240) on track for topline data in September 2026 CANYON-1 follows promising data from Phase 1a SAD/MAD study that demonstrated differentiated GI tolerability from GLP-1...

CRBP : 9.99 (-0.89%)
Corbus Pharmaceuticals Announces FDA Clearance to Initiate TEMPO-1 Registrational Study of CRB-701 in Patients with 2L Oropharyngeal Cancer

Company expects to initiate enrollment in TEMPO-1 in September 2026 OPSCC is estimated to represent 1 in 2 head and neck cancer patients in the 2L setting in the U.S. with approximately 14,000 patients...

CRBP : 9.99 (-0.89%)
Corbus Pharmaceuticals Appoints Leonardo Viana Nicacio, M.D. as Chief Medical Officer

NORWOOD, Mass., July 06, 2026 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a clinical-stage company focused on developing promising new...

CRBP : 9.99 (-0.89%)
Corbus Pharmaceuticals Targets HPV-Linked Head and Neck Cancer With CRB-701 Study

Corbus Pharmaceuticals (NASDAQ:CRBP) executives and oncology specialists used an ASCO-linked discussion to outline the rationale for focusing the company’s CRB-701 program on recurrent or metastatic...

CRBP : 9.99 (-0.89%)
Corbus Pharmaceuticals Reports Updated CRB-701 Phase 1/2 Clinical Data Demonstrating Robust Activity in 2L Oropharyngeal and Cervical Cancers

Data affirms Corbus strategy of targeting tumor types with elevated Nectin-4 expression and clear unmet medical needs while providing an attractive commercial path forward Confirmed ORR of 42.9% observed...

CRBP : 9.99 (-0.89%)
Corbus Pharmaceuticals Teases Key ASCO Cancer Data, Late-Summer Obesity Readout

Corbus Pharmaceuticals (NASDAQ:CRBP) Chief Executive Officer Yuval Cohen said investors should expect more mature clinical updates for CRB-701 at the upcoming ASCO meeting, including the first durability...

CRBP : 9.99 (-0.89%)
Corbus Pharmaceuticals Announces the Appointment of Nishant Saxena as Chief Business Officer and Schedules a Pre-2026 ASCO CRB-701 Data Conference Call

NORWOOD, Mass., May 21, 2026 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (Nasdaq: CRBP), a clinical-stage company focused on developing promising new therapies in oncology and obesity,...

CRBP : 9.99 (-0.89%)

Business Summary

Corbus Pharmaceuticals Holdings, Inc. is a Phase 3 clinical-stage pharmaceutical company focused on the development and commercialization of novel therapeutics to treat rare, chronic, and serious inflammatory and fibrotic diseases. The Company's lead product candidate, lenabasum, is a novel, synthetic...

See More

Key Turning Points

3rd Resistance Point 10.88
2nd Resistance Point 10.65
1st Resistance Point 10.32
Last Price 9.99
1st Support Level 9.76
2nd Support Level 9.53
3rd Support Level 9.20

See More

52-Week High 20.56
Fibonacci 61.8% 15.43
Fibonacci 50% 13.84
Fibonacci 38.2% 12.25
Last Price 9.99
52-Week Low 7.12

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.